GRANTS
| Investigation of activation of thrombosis in intensive blood flows |
| Identification of molecular determinants of cross-reactivity of T-cell receptors |
| The effect of chemotherapeutic drugs on the stromal microenvironment of the bone marrow in patients with hematoblastosis |
| Algorithms of "conversational intelligence" in the creation of medical record entries in a personal electronic medical record (medical history) |
| Development of a system for identifying psychopathological disorders and evaluating psychosocial indicators and the effectiveness of psychopharmaceutical and psychotherapy in patients with oncohematological diseases |
| Search for key paratopes of T-cell receptors specific to the minor histocompatibility antigen NA-2 |
| Minor histocompatibility antigen NA-1 as a target for immunotherapy of posttransplantation relapses of acute leukemia |
| Investigation of the mechanisms of immunomodulatory action of multipotent mesenchymal stromal cells injected into patients after allogeneic hematopoietic stem cell transplantation |
| Analysis of signaling pathway disorders and changes in the gene expression profile under the influence of mutational events in patients with Ph-negative acute lymphoblastic leukemia |
| Stromal progenitors in the bone marrow of patients with aplastic anemia |
CONTRACTS ON SCIENTIFIC AND TECHNICAL COOPERATION
| Determination of seropositivity (IgG class antibodies) to SARS Cov-2 in a cross section of samples |
| Determination of seropositivity (IgG class antibodies) to SARS Cov-2 in a cross section of samples |
| Development of a method for expression and isolation of the virus peplomer protein that causes the new coronavirus infection COVID-19 |
| Evaluation of G type immunoglobulin titers for SARS-CoV-2 virus in normal human Immunoglobulin preparations and blood samples by ELISA |
| Conducting a comparative study of a Reagent Kit and materials for the qualitative and/or quantitative determination of antibodies of the class immunoglobulins G (IgG) and/or immunoglobulins M (IgM) to the S and N proteins of the SARS-CoV-2 virus in blood samples from donors and convalescents, the content of antibodies of the class immunoglobulins G (IgG) is also characterized using the Reagent Kit for the immunoassay determination of IgG antibodies to the SARS-CoV-2 antigen in blood serum (plasma) of SARS-CoV-2-ELISA |
| Analysis of the immune response of T-lymphocytes from those recovered from COVID-19 to SARS-Co V-2 antigens |
| Selection of conditions for centrifugation of the medical device "Double AST Solopharm syringe" for obtaining platelet-enriched blood plasma |
| Development and validation of a methodology for assessing the presence of antibodies to erythropoietin conjugated with polysialic acid |
| Development of a methodology for determining the content of bacterial endotoxins (BE) in the preparations "Human albumin, 10%, 20;" manufactured by NPO “Microgen” |
| Production of mesenchymal stem cells of human red bone marrow |
